Safety and Efficacy Study of Pl-vegf165 to Treat Diabetic Foot Syndrome
Overview
- Phase
- Not Applicable
- Intervention
- Neovasculgen
- Conditions
- Ulcers Related to Diabetic Foot Syndrome
- Sponsor
- Human Stem Cell Institute, Russia
- Enrollment
- 35
- Locations
- 1
- Primary Endpoint
- Area of diabetic foot ulcers
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of this study is to determine whether pl-vegf165 (Neovasculgen) is effective in the treatment of ulcers related to diabetic foot syndrome
Detailed Description
This is a open clinical trial assessing the therapeutic efficacy of pl-vegf165 (Neovasculgen) in treating ulcers related to diabetic foot syndrome. Each patient will undergo several intramuscular injections with a treatment dose of pl-vegf165 (Neovasculgen) in calf of affected extrimity. Study participants at the first study visit will complete study questionnaires, their foots will be assessed clinically for ulceration. After this initial assessment, the patients will undergo intramuscular injections of pl-vegf165 (Neovasculgen) in a calf altered with ulcers due to diabetic foot syndrome. At three month post-injection, the patient will complete study questionnaires, their foots will be assessed clinically for ulceration, and their foots will undergo non-invasive transcutaneous oximetry measurement. At six months post-injection, the patient will again complete study questionnaires, their foots will be assessed clinically for ulceration and will undergo non-invasive transcutaneous oximetry measurement.
Investigators
Eligibility Criteria
Inclusion Criteria
- •obtained voluntary informed consent for participation in the clinical study
- •presence of diabetic foot syndrome
- •presence at least one active ulcer at baseline
Exclusion Criteria
- •Any disease that can, in the opinion of the treating physician, affect the outcome of the study
- •Patients with addictive disorders or substance abuse
- •Pregnancy or nursing
- •All other exclusion criteria listed in the summary of product characteristics (SmPC)
Arms & Interventions
Neovasculgen
Intervention: Neovasculgen
Outcomes
Primary Outcomes
Area of diabetic foot ulcers
Time Frame: 180 days
To determine the ability of pl-vegf165 to facilitate and accelerate diabetic foot ulcers healing
Secondary Outcomes
- Transcutaneous oxygen pressure(180 days)